Modulation of platelet-mediated innate immune responses in chronic lymphocytic leukaemia
Dr M Arman
31 March 2020
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the Western World. B-cell receptor-induced intracellular signals are critical for the survival of leukaemia cells and disruption of this pathway by the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib is a highly effective CLL therapy.